Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR4 | O00206 | 10/20 | 0.60 |
| ▸ | LY96 | Q9Y6Y9 | 6/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | LGALS8 | O00214 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | LGALS3 | P17931 | 1/20 | 0.38 |
| ▸ | LGALS4 | P56470 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23394777 | 1.00 | TLR4 (0.60) | TLR4LY96LMNAKMT2AMAPK1 | |
| SCHEMBL16883902 | 1.00 | TLR4 (0.60) | TLR4LY96LMNAKMT2AMAPK1 | |
| SCHEMBL16887431 | 1.00 | TLR4 (0.60) | TLR4LY96LMNAKMT2AMAPK1 | |
| SCHEMBL2341701 | 0.90 | MAPK1 (0.51) | TLR4LY96MAPK1ALDH1A1THRB | |
| SCHEMBL2341707 | 0.90 | MAPK1 (0.51) | TLR4LY96MAPK1ALDH1A1THRB | |
| SCHEMBL12391257 | 0.90 | MAPK1 (0.51) | TLR4LY96MAPK1ALDH1A1THRB | |
| SCHEMBL2338181 | 0.88 | TLR4 (0.65) | TLR4LY96LMNAKMT2ALGALS8 | |
| SCHEMBL17793805 | 0.88 | TLR4 (0.65) | TLR4LY96LMNAKMT2ALGALS8 | |
| SCHEMBL12391271 | 0.88 | TLR4 (0.65) | TLR4LY96LMNAKMT2ALGALS8 | |
| SCHEMBL3336078 | 0.87 | LMNA (0.54) | TLR4LY96LMNAKMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150191761-A1 | USE OF HIGH FLUX SCFA-DERIVATIZED MONOSACCHARIDES IN RECOMBINANT GLYCOPROTEIN PRODUCTION | THE JOHNS HOPKINS UNIVERSITY | 2015-07-09 | — | — | US | disclosed |
| US-8962638-B2 | Piperidine inhibitors of janus kinase 3 | AUSPEX PHARMACEUTICALS, INC. (US) | 2015-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150191761-A1 | USE OF HIGH FLUX SCFA-DERIVATIZED MONOSACCHARIDES IN RECOMBINANT GLYCOPROTEIN PRODUCTION | SLC35A1, FUT5, SLC17A5 | TLR4 1611/4885LY96 681/4885LMNA 4474/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.